Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation-Reference-Cited by-同舟云学术

Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation

Published:2017-09 Issue:9 Volume:48 Page:2494-2503
ISSN:0039-2499
Container-title:Stroke
language:en
Short-container-title:Stroke

Author:

Ntaios George¹,Papavasileiou Vasileios¹,Makaritsis Konstantinos¹,Vemmos Konstantinos¹,Michel Patrik¹,Lip Gregory Y.H.¹

Affiliation:

1. From the Department of Medicine, University of Thessaly, Larissa, Greece (G.N., K.M.); Stroke Service, Department of Neurosciences, Leeds Teaching Hospitals NHS Trust and Medical School, University of Leeds, United Kingdom (V.P.); Hellenic Cardiovascular Research Society, Athens, Greece (K.V.); Stroke Center, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Switzerland (P.M.); Institute of Cardiovascular Sciences, University of Birmingham Centre, United Kingdom (G.Y.H.L.); and...

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Advanced and Specialized Nursing,Cardiology and Cardiovascular Medicine,Neurology (clinical)

Reference43 articles.

1. Understanding controlled trials: Why are randomised controlled trials important?

2. The European Stroke Organisation Guidelines: a standard operating procedure

3. Real-World Evidence — What Is It and What Can It Tell Us?

4. Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel

5. Dabigatran versus Warfarin in Patients with Atrial Fibrillation

Cited by 193 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Apixaban, edoxaban and rivaroxaban but not dabigatran are associated with higher mortality compared to vitamin‐K antagonists: A retrospective German claims data analysis;Journal of Internal Medicine;2024-09-02

2. Risk Factors for Emergency Room Visits in Patients with Digestive Bleeding Associated with Direct-Acting Anticoagulants;Emergency Care and Medicine;2024-07-03

3. Use of apixaban in adults with congenital heart disease and atrial arrhythmias: The PROTECT-AR study;International Journal of Cardiology;2024-07

4. Time-in-therapeutic-range defined warfarin and direct oral anticoagulants in atrial fibrillation: a Nationwide Cohort Study;Annals of Medicine;2024-06-14

5. Idarucizumab in dabigatran-treated patients with acute stroke: a review and clinical update;Frontiers in Neurology;2024-05-16